Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer

References

• Greco AF, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, 9th edn. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011:2033-51
   Google Scholar
• Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Guidelines: occult primary (cancer of unknown primary [CUP]). Version 1.2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/occult.pdf [Last accessed 13 June 2013]
   Google Scholar
• Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 2010;18:3-8
   PubMedGoogle Scholar
• Varadhachary GR, Raber MN, Matamoros A, et al. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008;9:596-9
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007;43:2026-36
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Schnabel CA, Erlander MG, et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 2012;11:112-18
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013;31:217-23
   PubMed Web of Science ®Google Scholar
• Natoli C, Ramazzotti V, Nappi O, et al. Unknown primary tumors. Biochim Biophys Acta 2011;1816:13-24
   Google Scholar
• Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995;155:2050-4
   PubMedGoogle Scholar
• Saliminejad M, Bemanian S, Ho A, et al. The yield and cost of colonoscopy in patients with metastatic cancer of unknown primary. Aliment Pharmacol Ther 2013;38:628-33
   Google Scholar
• Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-73
   PubMed Web of Science ®Google Scholar
• Erlander MG, Ma XJ, Kesty NC, et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn 2011;13:493-503
   PubMed Web of Science ®Google Scholar
• Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 2012;18:3952-60
   PubMed Web of Science ®Google Scholar
• Pillai R, Deeter R, Rigl CT, et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 2011;13:48-56
   PubMed Web of Science ®Google Scholar
• Meiri E, Mueller WC, Rosenwald S, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012;17:801-12
   PubMed Web of Science ®Google Scholar
• Weiss LM, Chu P, Schroeder BE, et al. Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn 2013;15:263-9
   PubMed Web of Science ®Google Scholar
• Kim B, Schroeder BE, Schnabel CA, et al. Physician-reported clinical utility of the 92-gene molecular classifier in tumors with uncertain diagnosis following standard clinicopathologic evaluation. Personalized Med Onc 2013;2:68-76
   Google Scholar
• SEER Incidence Analysis; 2009 Incidence Rate Based on SEER 9 Regs Research Data, Nov 2011 Sub, Vintage 2009 Pops (1973–2009) <Katrina/Rita Population Adjustment> – Linked To County Attributes – Total U.S., 1969–2010 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, April 2012
   Google Scholar
• SEER Survival Analysis; 5-Year (2005–2009) Observed Survival Based on SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973–2009 varying) – Linked To County Attributes – Total U.S., 1969–2010 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, April 2012
   Google Scholar
• Losa Gaspà F, Germá JR, Albareda JM, et al. Metastatic cancer presentation: validation of a diagnostic algorithm with 221 consecutive patients [in Spanish]. Rev Clin Esp 2002;202:313-19
   Google Scholar
• Møller AK, Loft A, Berthelsen AK, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist 2012;17:1146-54
   Google Scholar
• Kopp RP, Stroup SP, Schroeck FR, et al. Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database. J Urol 2012;187:2056-60
   Google Scholar
• Cao JQ, Rodrigues GB, Louie AV, et al. Systematic review of the cost-effectiveness of positron-emission tomography in staging on non–small-cell lung cancer and management of solitary pulmonary nodules. Clin Lung Cancer 2012;13:161-70
   PubMed Web of Science ®Google Scholar
• Russo A, Elixhauser A, Steiner C, Wier L. Hospitalbased ambulatory surgery, 2007. HCUP Statistical Brief #86. February 2010. Rockville, MD: Agency for Healthcare Research and Quality. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb86.pdf [Last accessed 14 March 2013]
   Google Scholar
• Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-41
   PubMed Web of Science ®Google Scholar
• Tong KB, Murtagh KN, Hubert H, et al. Patient survival and health care utilization in Medicare beneficiaries diagnosed with cancer of unknown primary. J Clin Oncol 2006;24(18S; June 20 Suppl):6064
   Google Scholar
• Chong CAKY, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-8
   PubMed Web of Science ®Google Scholar
• Stein K, Sugar C, Velikova G, et al. Putting the ‘Q’ in quality adjusted life years (QALYs) for advanced ovarian cancer – an approach using data clustering methods and the internet. Eur J Cancer 2007;43:104-13
   Google Scholar
• Müller-Nordhorn J, Roll S, Böhmig M, et al. Health-related quality of life in patients with pancreatic cancer. Digestion 2006;74:118-25
   PubMed Web of Science ®Google Scholar
• Bremner KE, Chong CAKY, Tomlinson G, et al. A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007;27:288-98
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Z, Barber B, et al. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 2011;104:1848-53
   PubMed Web of Science ®Google Scholar
• Swinburn P, Lloyd A, Nathan P, et al. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin 2010;26:1091-6
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84-99
   PubMed Web of Science ®Google Scholar
• NICE Clinical Guidelines, No. 104. Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin. Cardiff, UK: National Collaborating Centre for Cancer (UK), July 2010
   Google Scholar
• US Department of Labor. Archived Consumer Price Index Detailed Report Information. Available at: http://www.bls.gov/cpi/cpi_dr.htm [Last accessed 30 March 2013]
   Google Scholar
• Physicians’ Fee & Coding Guide 2012. Atlanta, GA: MAG Mutual Healthcare Solutions, 2011
   Google Scholar
• Behl AS, Goddard KAB, Flottemesch TJ, et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012;104:1785-95
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56
   PubMed Web of Science ®Google Scholar
• Gold HT, Hayes MK. Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations. Breast Cancer Res Treat 2012;136:221-9
   Google Scholar
• Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol 2013;108:120-32
   Google Scholar
• Wang G, Kuppermann M, Kim B, et al. Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. Am J Manag Care 2012;18:e179-85
   Google Scholar
• Tsoi DT, Inoue M, Kelly CM, et al. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 2010;15:457-65
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Garrison LP, Ramsey SD, et al. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009;12:20-7
   PubMed Web of Science ®Google Scholar
• Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009;115:489-98
   PubMed Web of Science ®Google Scholar